Teclison

Teclison was founded with the vision of assembling leading scientists, advisors, and other leaders with significant pharmaceutical expertise to develop groundbreaking therapies for cancer. The company specializes in the development of innovative cancer medicines which induce tumor necrosis and enhance anti-tumor immunity for long-term cancer remission. The company’s drug is designed to treat any solid tumor with a predilection for liver metastasis, including hepatocellular carcinoma and metastatic colorectal cancer first, and expanding to other solid tumors with liver metastasis. Teclison’s novel approach is a first-in-class hypoxia-activating agent which achieves long-term remission in hard-to-treat cancer cell, cancer stem cells and tumor-promoting macrophage targets by creating high local concentration of its compound and producing profound hypoxia exclusively within the tumor